Bio-Path Holdings to Announce Third Quarter 2020 Financial Results on November 13, 2020

Rhea-AI Summary

Bio-Path Holdings, Inc. (NASDAQ: BPTH) will host a conference call and audio webcast on November 13, 2020, at 8:30 a.m. ET to discuss its third-quarter financial results for the period ending September 30, 2020. The company specializes in developing cancer treatments using its DNAbilize^® antisense RNAi nanoparticle technology. Its lead candidate, prexigebersen (BP1001), is advancing in a Phase 2 study for blood cancers, while prexigebersen-A is being considered for Phase 1 trials in solid tumors. Details for accessing the call are provided in the announcement.

Positive

• Lead product candidate, prexigebersen, progressing to Phase 2 study for blood cancers.
• Potential FDA consideration for prexigebersen-A to start Phase 1 studies in solid tumors.

Negative

• None.

HOUSTON, Nov. 06, 2020 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH), a biotechnology company leveraging its proprietary DNAbilize^® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that it will host a live conference call and audio webcast on Friday, November 13, 2020 at 8:30 a.m. ET to report financial results for the third quarter ended September 30, 2020 and to provide a business overview.

To access the live conference call, please call (844) 815-4963 (domestic) or (210) 229-8838 (international) at least five minutes prior to the start time and refer to conference ID 5878804. A live audio webcast of the call will also be available on the Presentations section of the Company’s website, www.biopathholdings.com. An archived webcast will be available on the Bio-Path website approximately two hours after the event.

About Bio-Path Holdings, Inc.

Bio-Path is a biotechnology company developing DNAbilize^®, a novel technology that has yielded a pipeline of RNAi nanoparticle drugs that can be administered with a simple intravenous transfusion. Bio-Path’s lead product candidate, prexigebersen (BP1001, targeting the Grb2 protein), is in a Phase 2 study for blood cancers and prexigebersen-A, a drug product modification of prexigebersen, is under consideration by the FDA to commence Phase 1 studies in solid tumors. This is followed by BP1002, targeting the Bcl-2 protein, where it will be evaluated in lymphoma and solid tumors clinical studies. For more information, please visit the Company's website at http://www.biopathholdings.com.

Contact Information:

Investors

Will O’Connor
Stern Investor Relations
212-362-1200
will@sternir.com

Doug Morris
Investor Relations
Bio-Path Holdings, Inc.
832-742-1369

FAQ

When will Bio-Path Holdings announce its third-quarter financial results?

Bio-Path Holdings will announce its third-quarter financial results on November 13, 2020.

What is the main product being developed by Bio-Path Holdings?

Bio-Path Holdings is primarily developing prexigebersen (BP1001) for blood cancers.

How can I access the Bio-Path Holdings conference call?

You can access the Bio-Path Holdings conference call by calling (844) 815-4963 domestically or (210) 229-8838 internationally, or via the audio webcast on their website.